Chromatin Regulator-Related Gene Signature for Predicting Prognosis and Immunotherapy Efficacy in Breast Cancer

Figure 4

Kaplan–Meier survival subgroup analysis in BC patients from the TCGA training set based on the 6-gene signature stratified by clinical characteristics. The OS differences between low- and high-risk group stratified by age (≤60 years and >60 years, respectively) (a) and (b). The OS differences between low-and high-risk group stratified by T stage (T1-2 and T3-4, respectively) (c) and (d). The OS differences between low- and high-risk group stratified by N (−) and N (+) stage. (N0 and N1–3, respectively) (e) and (f). The OS differences between low- and high-risk group stratified by M stage (M0 and M1, respectively) (g) and (h).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)